[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Pages 43392-43393]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19590]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Government owned intellectual property covering imaging agents 
with improved renal clearance available for licensing and 
commercialization.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The inventions listed below are owned by an 
agency of the U.S. Government and are available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. A description of the technology available for 
licensing follows.

Methods of Using Inhibitors To Enhance Therapeutic Uses of 
Endocannabinoids

    Description of Technology: The invention pertains to methods of 
using compounds that inhibit fatty acid amide hydrolase (FAAH) enzymes 
that are responsible for the degradation of oleamide and anandamide. 
Inhibition of degradation can be used as treatment modality for 
hypertension and for sleep disorders. The issued patent lists 
potentially useful compounds, one such useful compound in particular is
[GRAPHIC] [TIFF OMITTED] TN15SE.001


[[Page 43393]]


Potential Commercial Applications:
    <bullet> Therapeutics for hypertension
    <bullet> Therapeutics for anxiety disorders
    <bullet> Therapeutics for sleep disorders
Development Stage:
    <bullet> In vivo data available
Inventors: George Kunos and Alexandros Makriyannis (both of NIAAA)
Intellectual Property: HHS Reference No. E-211-2006/0-US-06.
    <bullet> U.S. Patent 8,293,724 filed April 6, 2010, issued October 
23, 2012.

    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
<a href="/cdn-cgi/l/email-protection#a7d4cfcacecbc8d1cae7c9cecf89c0c8d1"><span class="__cf_email__" data-cfemail="64170c090d080b1209240a0d0c4a030b12">[email protected]</span></a>.
    Collaborative Research Opportunity: The National Institute of 
Environmental Health Sciences seeks statements of capability or 
interest from parties interested in collaborative research to further 
develop and evaluate, please contact Peg Koelble, Office of Technology 
Transfer, National Heart, Lung and Blood Institute, 
<a href="/cdn-cgi/l/email-protection#33585c565f515f5643735d5b5f515a1d5d5a5b1d545c45"><span class="__cf_email__" data-cfemail="7813171d141a141d08381610141a1156161110561f170e">[email protected]</span></a>, 301-594-4095.

    Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-19590 Filed 9-14-17; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>